Back to Search Start Over

NKp46-expressing human gut-resident intraepithelial Vδ1 T cell subpopulation exhibits high antitumor activity against colorectal cancer.

Authors :
Mikulak J
Oriolo F
Bruni E
Roberto A
Colombo FS
Villa A
Bosticardo M
Bortolomai I
Lo Presti E
Meraviglia S
Dieli F
Vetrano S
Danese S
Della Bella S
Carvello MM
Sacchi M
Cugini G
Colombo G
Klinger M
Spaggiari P
Roncalli M
Prinz I
Ravens S
di Lorenzo B
Marcenaro E
Silva-Santos B
Spinelli A
Mavilio D
Source :
JCI insight [JCI Insight] 2019 Dec 19; Vol. 4 (24). Date of Electronic Publication: 2019 Dec 19.
Publication Year :
2019

Abstract

γδ T cells account for a large fraction of human intestinal intraepithelial lymphocytes (IELs) endowed with potent antitumor activities. However, little is known about their origin, phenotype, and clinical relevance in colorectal cancer (CRC). To determine γδ IEL gut specificity, homing, and functions, γδ T cells were purified from human healthy blood, lymph nodes, liver, skin, and intestine, either disease-free, affected by CRC, or generated from thymic precursors. The constitutive expression of NKp46 specifically identifies a subset of cytotoxic Vδ1 T cells representing the largest fraction of gut-resident IELs. The ontogeny and gut-tropism of NKp46+/Vδ1 IELs depends both on distinctive features of Vδ1 thymic precursors and gut-environmental factors. Either the constitutive presence of NKp46 on tissue-resident Vδ1 intestinal IELs or its induced expression on IL-2/IL-15-activated Vδ1 thymocytes are associated with antitumor functions. Higher frequencies of NKp46+/Vδ1 IELs in tumor-free specimens from CRC patients correlate with a lower risk of developing metastatic III/IV disease stages. Additionally, our in vitro settings reproducing CRC tumor microenvironment inhibited the expansion of NKp46+/Vδ1 cells from activated thymic precursors. These results parallel the very low frequencies of NKp46+/Vδ1 IELs able to infiltrate CRC, thus providing insights to either follow-up cancer progression or to develop adoptive cellular therapies.

Details

Language :
English
ISSN :
2379-3708
Volume :
4
Issue :
24
Database :
MEDLINE
Journal :
JCI insight
Publication Type :
Academic Journal
Accession number :
31689241
Full Text :
https://doi.org/10.1172/jci.insight.125884